Eisai May Resubmit Aricept Severe Alzheimer’s sNDA In Electronic Format
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Eisai is considering an electronic format for a mid-December resubmission of an sNDA for Aricept treatment of severe Alzheimer’s disease.
You may also be interested in...
Eisai Rufinamide Electronic Resubmission Aims To Make NDA More Accessible
Formatting issues with Eisai's original rufinamide anti-epilepsy NDA could result in a more than two-month delay in approval
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011